Evidence map›Paper›PMID 38904265›Full record

ArticleCancer research communications2024

The Tumor Microbiome Reacts to Hypoxia and Can Influence Response to Radiation Treatment in Colorectal Cancer.

Martin Benej, Rebecca Hoyd, McKenzie Kreamer, Caroline E Wheeler, Dennis J Grencewicz, Fouad Choueiry, Carlos H F Chan, Yousef Zakharia, Qin Ma, Rebecca D Dodd and 23 more

Registry-linked trialAbstract read
In one paragraph

Article in Cancer research communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02328677 (ColoCare Transdisciplinary Research in Colorectal Cancer Prognosis), which is not on this map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02328677 recruitingnot on this map

ColoCare Transdisciplinary Research in Colorectal Cancer Prognosis

TypeobservationalSponsorUniversity of UtahRan2007 to 2030Enrolled5,000ConditionsColorectal Cancer
3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

Martin BenejDepartment of Radiation Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Rebecca HoydDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.ORCID 0000-0003-1210-4491
McKenzie KreamerDepartment of Radiation Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Caroline E WheelerDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.ORCID 0000-0002-3374-4909
Dennis J GrencewiczDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Fouad ChoueiryDepartment of Health Sciences, The Ohio State University, Columbus, Ohio.ORCID 0009-0002-3350-8217
Carlos H F ChanHolden Comprehensive Cancer Center, University of Iowa, Iowa City, Iowa.
Yousef ZakhariaDivision of Oncology, Hematology and Blood & Marrow Transplantation, Holden Comprehensive Cancer Center, University of Iowa, Iowa City, Iowa.ORCID 0000-0001-9480-2626
Qin MaDepartment of Biomedical Informatics, The Ohio State University, Columbus, Ohio.ORCID 0000-0002-3264-8392
Rebecca D DoddDepartment of Internal Medicine, University of Iowa, Iowa City, Iowa.ORCID 0000-0001-7295-1882
Cornelia M UlrichDepartment of Population Health Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.ORCID 0000-0001-7641-059X
Sheetal HardikarDepartment of Population Health Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.ORCID 0000-0003-0292-6168
Michelle L ChurchmanAster Insights, Hudson, Florida.
Ahmad A TarhiniDepartment of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.ORCID 0000-0002-3193-9702
Lary A RobinsonDepartment of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
Eric A SingerDepartment of Urologic Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Alexandra P IkeguchiDepartment of Hematology/Oncology, Stephenson Cancer Center of University of Oklahoma, Oklahoma City, Oklahoma.
Martin D McCarterDepartment of Surgery, University of Colorado School of Medicine, Aurora, Colorado.ORCID 0000-0001-8174-1713
Gabriel TinocoDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.ORCID 0000-0002-2565-6124
Marium HusainDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Ning JinDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Aik C TanDepartment of Oncological Science, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
Afaf E G OsmanDepartment of Internal Medicine, University of Utah, Salt Lake City, Utah.
Islam EljilanyDepartment of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
Gregory RiedlingerDepartment of Precision Medicine, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.
Bryan P SchneiderIndiana University Simon Comprehensive Cancer Center, Indianapolis, Indiana.ORCID 0000-0003-1868-7739
Katarina BenejovaDepartment of Radiation Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Martin KeryDepartment of Radiation Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Ioanna PapandreouDepartment of Radiation Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.ORCID 0000-0002-4458-6010
Jiangjiang ZhuDepartment of Health Sciences, The Ohio State University, Columbus, Ohio.
Nicholas DenkoDepartment of Radiation Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Daniel SpakowiczDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.ORCID 0000-0003-2314-6435
exORIEN Consortium

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Jennifer A. Woyach · 1985 to 2026
$132.3M
The Ohio State University Center for Clinical and Translational Science (UL1)UL1TR000090 · NCATS · OHIO STATE UNIVERSITY · PI JACKSON, REBECCA D · 2012 to 2013
$7.9M
Geriatric assessment domains in relation to treatment outcomes among older adults with colorectal cancerR01AG083580 · NIA · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Sheetal Hardikar · 2024 to 2026
$2.3M
Diabetes, Medications and the Cost-Effectiveness of Screening for Colorectal NeoplasiaK07CA222060 · NCI · UNIVERSITY OF UTAH · PI HARDIKAR, SHEETAL · 2018 to 2022
$791k
Autism Speaks AS1695NCATS NIH HHS UL1 TR000090NCI NIH HHS K07 CA222060NCI NIH HHS P30 CA016058NIA NIH HHS R01 AG083580
6 · The paper itself

Abstract

Tumor hypoxia has been shown to predict poor patient outcomes in several cancer types, partially because it reduces radiation's ability to kill cells. We hypothesized that some of the clinical effects of hypoxia could also be due to its impact on the tumor microbiome. Therefore, we examined the RNA sequencing data from the Oncology Research Information Exchange Network database of patients with colorectal cancer treated with radiotherapy. We identified microbial RNAs for each tumor and related them to the hypoxic gene expression scores calculated from host mRNA. Our analysis showed that the hypoxia expression score predicted poor patient outcomes and identified tumors enriched with certain microbes such as Fusobacterium nucleatum. The presence of other microbes, such as Fusobacterium canifelinum, predicted poor patient outcomes, suggesting a potential interaction between hypoxia, the microbiome, and radiation response. To experimentally investigate this concept, we implanted CT26 colorectal cancer cells into immune-competent BALB/c and immune-deficient athymic nude mice. After growth, in which tumors passively acquired microbes from the gastrointestinal tract, we harvested tumors, extracted nucleic acids, and sequenced host and microbial RNAs. We stratified tumors based on their hypoxia score and performed a metatranscriptomic analysis of microbial gene expression. In addition to hypoxia-tropic and -phobic microbial populations, analysis of microbial gene expression at the strain level showed expression differences based on the hypoxia score. Thus, hypoxia gene expression scores seem to associate with different microbial populations and elicit an adaptive transcriptional response in intratumoral microbes, potentially influencing clinical outcomes. SIGNIFICANCE: Tumor hypoxia reduces radiotherapy efficacy. In this study, we explored whether some of the clinical effects of hypoxia could be due to interaction with the tumor microbiome. Hypoxic gene expression scores associated with certain microbes and elicited an adaptive transcriptional response in others that could contribute to poor clinical outcomes.

Indexed as

Colorectal NeoplasmsMice, Inbred BALB CMice, NudeTumor HypoxiaAnimalsCell Line, TumorFemaleHumansMiceMicrobiota

Identifiers

PMID38904265
PMCPMC11234499

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.